Jonas Grossman - 01 Dec 2022 Form 4 Insider Report for Renovacor, Inc.

Role
Director
Signature
/s/ Joseph Carroll, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Dec 2022
Net transactions value
$0
Form type
4
Filing time
05 Dec 2022, 20:23:28 UTC
Previous filing
12 Oct 2022
Next filing
13 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCOR Common Stock Disposed to Issuer -394,657 -100% 0 01 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCOR Stock Option Disposed to Issuer $0 -24,000 -100% $0.000000* 0 01 Dec 2022 Common Stock 24,000 Direct F2, F3
transaction RCOR Stock Option Disposed to Issuer $0 -12,000 -100% $0.000000* 0 01 Dec 2022 Common Stock 12,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jonas Grossman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement") in exchange for 69,578 shares of Rocket common stock having a market value of $18.39 per share on the effective date of the merger.
F2 Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F3 Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.